Semaglutide vs Tirzepatide
Reviewed by the BestHealingPeptides Editorial Team ·
Semaglutide and tirzepatide are the two most clinically significant incretin-pathway peptide drugs of the late 2020s. Both are MHRA-licensed for type-2 diabetes and chronic weight management, both are administered as once-weekly subcutaneous injections, both are products of similar peptide-engineering principles (Aib substitution for DPP-4 resistance, fatty-acid acylation for albumin binding). The fundamental pharmacological difference is receptor pharmacology: semaglutide is a selective GLP-1 receptor agonist; tirzepatide adds GIP receptor agonism for dual-receptor pharmacology. Head-to-head trials (SURPASS-2, SURMOUNT-5) confirm tirzepatide produces superior HbA1c reduction and weight loss at the maximum licensed doses of each.
Semaglutide
A long-acting GLP-1 receptor agonist developed by Novo Nordisk, modified from native GLP-1 with aminoisobutyric acid (Aib) at position 8 (DPP-4 resistance) and a C18 fatty diacid moiety on lysine 26 (albumin binding for ~1-week half-life). Licensed in the UK by the MHRA for type-2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and chronic weight management (Wegovy, subcutaneous). The most clinically significant GLP-1 receptor agonist of the late 2020s.
Tirzepatide
A 39-amino-acid synthetic peptide developed by Eli Lilly as a dual GIPR/GLP-1R co-agonist — the first commercially successful dual incretin receptor agonist. Engineered with C20 fatty diacid acylation on lysine 20 for albumin binding and weekly dosing. Licensed in the UK by the MHRA for type-2 diabetes (Mounjaro) and chronic weight management (Zepbound). Produces larger weight loss than semaglutide in head-to-head trials (SURPASS-2, SURMOUNT-5).
| Aspect | Semaglutide | Tirzepatide |
|---|---|---|
| Receptor pharmacology | Selective GLP-1R agonist | Dual GLP-1R + GIPR co-agonist |
| Plasma half-life | ~7 days (C18 fatty diacid acylation) | ~5 days (C20 fatty diacid acylation) |
| UK licensed brands | Ozempic (T2DM); Wegovy (obesity); Rybelsus (oral T2DM) | Mounjaro (T2DM); Zepbound (obesity) |
| Max weight loss (head-to-head) | ~14% mean (Wegovy 2.4 mg, STEP 1) | ~20% mean (Zepbound 15 mg, SURMOUNT-1) |
| Max HbA1c reduction (SURPASS-2) | -1.86% (semaglutide 1.0 mg) | -2.30% (tirzepatide 15 mg) |
| CV outcomes data | SUSTAIN-6 ✓ SELECT ✓ — established MACE reduction | SURPASS-CVOT ongoing — expected positive |
| Oral formulation | Rybelsus (SNAC-enhanced) | None licensed |
| WADA status | Not on Prohibited List 2026 | Not on Prohibited List 2026 |
Receptor pharmacology — the core difference
Semaglutide is a selective full agonist of the glucagon-like peptide-1 receptor (GLP-1R) — the same class as liraglutide, dulaglutide, and exenatide before it. Receptor activation drives Gαs/cAMP signalling on pancreatic β-cells (glucose-dependent insulin secretion), α-cells (glucagon suppression), central neurons (appetite suppression), and peripheral tissues. Tirzepatide is a dual agonist of GLP-1R AND the glucose-dependent insulinotropic peptide receptor (GIPR), with binding affinities approximately 5-fold higher at GIPR than at GLP-1R relative to the respective native ligands. The added GIPR pharmacology engages β-cell insulinotropic effects through a parallel cAMP cascade and additional effects on adipose-tissue lipogenesis and lipolysis through GIPR expression on adipocytes. Combined receptor activation produces additive metabolic benefits beyond GLP-1R monoagonism.
Head-to-head efficacy — tirzepatide superior at maximum doses
Two pivotal head-to-head trials have established tirzepatide's superiority over semaglutide. SURPASS-2 (Frías et al., NEJM 2021) tested tirzepatide 5, 10, and 15 mg weekly versus semaglutide 1.0 mg weekly in 1,879 type-2 diabetes patients over 40 weeks. All three tirzepatide doses produced superior HbA1c reduction (-2.30% vs -1.86% at 15 mg vs 1.0 mg) and superior weight loss (-12.4 kg vs -6.2 kg at the same comparison). SURMOUNT-5 (published 2024) tested tirzepatide 15 mg weekly versus semaglutide 2.4 mg weekly (Wegovy dose) in non-diabetic obese subjects: tirzepatide produced ~20% mean body weight loss versus ~14% for semaglutide. At maximum licensed doses for each compound, tirzepatide produces materially greater efficacy across glycaemic and weight outcomes. The mechanistic explanation for the additional efficacy — whether GIPR full agonism, biased agonism, or even functional antagonism contributes most — remains an open research question.
Adverse-event profile — broadly similar with some differences
The adverse-event profiles are broadly similar at the class level: gastrointestinal symptoms dominate (nausea, vomiting, diarrhoea, constipation), are dose-dependent, are most prominent during dose titration, and account for the majority of treatment discontinuations. Severe hypoglycaemia is rare with either compound in monotherapy due to the strictly glucose-dependent insulinotropic mechanism. The thyroid C-cell carcinoma class warning applies to both. Acute pancreatitis, biliary disease related to rapid weight loss, modest heart rate elevation, and rare diabetic retinopathy progression are documented for both. The largest single difference in tolerability is that tirzepatide's higher target doses (12.5, 15 mg) produce a somewhat heavier GI burden than semaglutide's target doses (2.0 mg Ozempic, 2.4 mg Wegovy), reflecting the larger pharmacodynamic effect rather than any mechanism-specific toxicity. Both are generally well-tolerated with appropriate dose titration.
Pharmacokinetics and dosing — both once weekly
Semaglutide has a ~7-day plasma half-life through C18 fatty diacid albumin binding; tirzepatide has a ~5-day half-life through C20 fatty diacid acylation. Both support once-weekly subcutaneous dosing. Semaglutide's higher half-life translates to longer steady-state buildup and somewhat smoother plasma profiles between doses. Both products are dispensed as pre-filled multi-dose pens or single-dose pre-filled syringes; both require refrigerated storage before first use and limited room-temperature stability after first use. Semaglutide additionally has the oral formulation (Rybelsus) co-formulated with SNAC absorption enhancer — no oral tirzepatide formulation is currently licensed (though oral incretin formulations are in development across the field).
UK access and cost
Both are MHRA-licensed POMs available through NHS prescription within NICE technology appraisal criteria and through private prescription. NHS Wegovy access through specialist obesity services has been expanding through 2025-2026; NHS Mounjaro and Zepbound similarly. NHS Ozempic prescription in type-2 diabetes is routine within NICE TA664. Private prescription costs are comparable between the two compounds. Both have experienced UK supply constraints during 2023-2024, partially resolved by 2025-2026. Counterfeit supply through unauthorised online channels has been an MHRA enforcement concern for both products.
Verdict
Tirzepatide produces superior HbA1c reduction and superior weight loss versus semaglutide at the respective maximum licensed doses, supported by two large head-to-head Phase III trials (SURPASS-2 and SURMOUNT-5). For efficacy-first prescribing decisions, tirzepatide is the choice. Semaglutide retains advantages in the longer post-marketing safety dataset (Ozempic has been licensed since 2017 vs Mounjaro since 2022), the broader range of formulations (including the only licensed oral GLP-1R agonist Rybelsus), and somewhat better-established cardiovascular outcomes data through SUSTAIN-6 and SELECT (the tirzepatide CV outcomes trial SURPASS-CVOT is ongoing). For patients with similar response to either, semaglutide is the historically more conservative choice; for patients prioritising maximum weight loss or HbA1c reduction, tirzepatide is the higher-efficacy choice.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.